Other urogenital candidiasis
Methodology & AI Transparency ⓘ
Other urogenital candidiasis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code B37.49 in Infections & Antivirals, Other urogenital candidiasis requires sepsis/severity red-flag triage [Other urogenital candidiasis B37.49] so specialists can calibrate treatment intensity against C-Reactive Protein / in Other urogenital candidiasis (B37.49: Procalcitonin) benchmarks.
- 2 Real-world patient consensus: Clinical coding for Other urogenital candidiasis uses ICD-10 B37.49 across Infections & Antivirals specialty care.
- 3 Typical cash cost range: Primary evaluation for Other urogenital candidiasis incorporates sepsis/severity red-flag triage [Other urogenital candidiasis B37.49] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Other urogenital candidiasis monitoring tracks C-Reactive Protein / in Other urogenital candidiasis (B37.49: Procalcitonin) toward Resolution to baseline (B37.49).
Ask our AI Specialists anything about Other urogenital candidiasis
What Is Other urogenital candidiasis?
Cataloged under federal diagnostic code B37.49 in Infections & Antivirals, Other urogenital candidiasis requires sepsis/severity red-flag triage [Other urogenital candidiasis B37.49] so specialists can calibrate treatment intensity against C-Reactive Protein / in Other urogenital candidiasis (B37.49: Procalcitonin) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Other urogenital candidiasis (B37.49) center on or latent viral in Other urogenital candidiasis (B37.49: reactivation within sensory). targeted infections & antivirals interventions aim to normalize C-Reactive Protein / in Other urogenital candidiasis (B37.49: Procalcitonin).
Common Symptoms & Clinical Signs
- • Presentation of Other urogenital candidiasis (B37.49): regional lymph node in Other urogenital candidiasis (B37.49: tenderness or acute)
- • Secondary Other urogenital candidiasis clinical sign: acute fever, chills, in Other urogenital candidiasis (B37.49: malaise, and myalgias)
- • Symptom flares in Other urogenital candidiasis correlating with C-Reactive Protein / in Other urogenital candidiasis (B37.49: Procalcitonin) deviation outside Resolution to baseline (B37.49)
- • Functional infections & antivirals impact requiring sepsis/severity red-flag triage [Other urogenital candidiasis B37.49] evaluation (B37.49)
Other urogenital candidiasis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B37.49 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NLM Clinical Tables |
| Diagnostic / Lab Marker: C-Reactive Protein / in Other urogenital candidiasis (B37.49: Procalcitonin) | Resolution to baseline (B37.49) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Other urogenital candidiasis (B37.49: Culture & Sensitivity) | Pathogen clearance / negative test (B37.49) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Other urogenital candidiasis (B37.49: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B37.49) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other urogenital candidiasis
Treatment selection for Other urogenital candidiasis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other urogenital candidiasis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
| New Insights on Telmisartan and amlodipine single-pill combinations vs amlodipine single-drug: What a 1,097-Participant Study Found Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled. Journal of clinical hypertension (Greenwich, Conn.) • 2011-07-15 • Randomized Controlled Trial | N = 1,097 | 96/100 | PMID 21762357 ↗ |
Other urogenital candidiasis Patient Community & “People Like Me” Threads
Filter Other urogenital candidiasis community threads and patient logs by age, biological sex, dosage, and treatment duration.